Semaglutide’s dilemma: A lifesaver with a price?

Abstract Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has revolutionized the treatment landscape for type 2 diabetes and obesity. This review explores the dual nature of Semaglutide, highlighting its substantial benefits while acknowledging potential drawbacks. Clinical studies demonstrate that semaglutide effectively lowers HbA1c levels by 1.5–2.0% and promotes significant weight loss, with reductions of up to 14.9% observed in patients with obesity. Additionally, Semaglutide has been associated with a 20% reduction in the risk of major adverse cardiovascular events, underscoring its multifaceted therapeutic potential. However, semaglutide is not without risks. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhoea, affecting a notable percentage of users. Serious concerns, including potential pancreatitis and thyroid tumours, have also been raised, necessitating careful patient selection and monitoring. Moreover, the long-term safety profile remains uncertain, with ongoing studies needed to assess the implications of prolonged use. Despite its high cost and the challenges of injection administration, semaglutide’s effectiveness in managing metabolic disorders makes it a valuable tool in clinical practice. As research progresses, understanding the balance between its remarkable benefits and potential risks will be essential for optimizing patient outcomes in diabetes and obesity management This article aims to provide a balanced perspective on semaglutide’s role in modern medicine, highlighting its potential as a powerful tool in metabolic health while acknowledging the need for ongoing research and careful clinical application.